Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma but are associated with immune‐related adverse events (irAEs). This single center, cross‐sectional survey aimed to describe the long‐term symptom burden and impact on health‐related quality of l...

Descripción completa

Detalles Bibliográficos
Autores principales: Looman, E. L., Cheng, P. F., Lai‐Kwon, J., Morgan, L., Wakkee, M., Dummer, R., Dimitriou, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278493/
https://www.ncbi.nlm.nih.gov/pubmed/37119050
http://dx.doi.org/10.1002/cam4.5967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278493/
https://www.ncbi.nlm.nih.gov/pubmed/37119050
http://dx.doi.org/10.1002/cam4.5967

Ejemplares similares